Bleeding recurrence in patients with gastrointestinal vascular malformation after thalidomide

Haiying Chen, MM, Sengwang Fu, MD, Nan Feng, MD, Huimin Chen, MD, Yunjie Gao, MB, Yunjia Zhao, MM, Hanbing Xue, MD, Yao Zhang, MD, Xiaobo Li, MD, Jun Dai, MM, Jingyuan Fang, MD, Zhizheng Ge, MD

Abstract
Thalidomide may be used for the treatment of gastrointestinal malformation (GIVM), but the long-term response and adverse effects are unknown. Aim to study the recurrence rate of GIVM bleeding after thalidomide treatment, the response to treatment, and the adverse effects.

This was a retrospective study of 80 patients with GIVM treated with thalidomide between November 2003 and November 2013. Patients received a course of 100 mg/day of thalidomide for 4 months and were followed up for at least 1 year. The response rate during follow-up, the recurrence rate after the 1st course of treatment, and the rate of retreatment were assessed. Comorbidities, the need for blood transfusion, yearly bleeding episodes, hemoglobin levels, hospitalization after thalidomide treatment, and the rate of adverse effects were also examined.

The overall response rate during follow-up was 79.5% (62/78). The recurrence rate was 21.0% after the 1st course of thalidomide. The response rate of retreatment was 100%. After thalidomide treatment, yearly blood transfusion amounts, yearly bleeding episodes, and yearly hospitalization numbers were significantly decreased, while hemoglobin levels were significantly increased (P < 0.001). Adverse effects were observed in 60.0% (48/80) of the patients. Serious adverse effects were reported in 31.3% (25/80). The overall response rate was 76.7% (23/30) in 30 patients with comorbidities, while the rate was 78.0% (39/50) in patients without comorbidities (P = 0.55). The rate of serious adverse effects was similar between the comorbidities (33.3%) and no-comorbidities groups (30.0%) (P = 0.76).

Thalidomide showed a good response rate and low adverse effect rate in patients with recurrent gastrointestinal bleeding due to GIVM.

Abbreviations: DBE = double balloon enteroscopy, GI = gastrointestinal, GIVM = gastrointestinal vascular malformation, HHT = hereditary hemorrhagic telangiectasia, iFOBT = immunoassay fecal occult blood test, SB = small bowel.

Keywords: adverse effects, gastrointestinal vascular malformation, recurrence rate, response rate, thalidomide

1. Introduction
Gastrointestinal (GI) vascular malformation (GIVM) is a hemorrhagic disease involving the entire GI tract. About 90% of cases are located in the small intestine. GIVM is the main cause of occult GI bleeding, particularly in the elderly. Approximately 20% of the patients present iron-deficiency anemia and/or stools with intermittently positive fecal occult blood test. Massive bleeding occurs in about 12% to 27% of the patients, and 50% of the patients need frequent hospitalization and repeated blood transfusions.

Conventional interventional therapies are often ineffective in preventing recurrent GI bleeding and may occasionally be associated with severe complications. Some drugs were previously considered promising, but a recent randomized study found that such a treatment was ineffective. Other medicines like danazol, tranexamic acid, desmopressin, and recombinant factor VIIa were considered effective but without confirmation using a randomized controlled study. Junquera et al demonstrated a lower recurrence rate in patients receiving octreotide compared with the placebo group.

An effective and relatively safe pharmaceutical agent is still needed. Thalidomide possesses antiangiogenesis properties via the suppression of the vascular endothelial growth factor, which has been shown to be strongly expressed in GIVM. Thalidomide also possesses immunomodulating, antitumor, and antiinflammatory properties, but its nefarious teratogenic effects may limit its use. Thalidomide was successfully used for the treatment of recurrent gastric bleeding in a patient with hereditary hemorrhagic telangiectasia (HHT) and for the...
treatment of cirrhotic patients with severe anemia secondary to vascular malformation.\[10]\]

Our group reported a response rate of 71.4% for thalidomide in patients with refractory GI bleeding due to GIVM at 1 year follow-up.\[14\] Therefore, this study aimed to assess the long-term response of GIVM to thalidomide, as well as the adverse effects.

2. Methods

2.1. Patients

This was a retrospective study of patients diagnosed with GIVM at the Department of Gastroenterology, Renji Hospital, from November 2003 to November 2013. Because of the lack of a universally accepted classification system for GIVM, radiological diagnoses of angiodysplasia, vascular ectasia, arteriovenous malformation, vascular malformation, or angioma were included in this study.\[11\]

Inclusion criteria were: aged ≥18 years; male or female patients, but female patients were postmenopausal, with postpubertal ligation, or females with childbearing potential using any form of birth control; patients had recurrent (≥4 bleeding episodes in the year prior treatment) or refractory bleeding due to GIVM; and all confirmed GIVM without obvious infectious, cancers, or other specific lesions, based on comprehensive examinations.

Refractory bleeding was defined as bleeding that is either unresponsive to conventional therapies (i.e., recurrent bleeding after at least 3 sessions of esophagogastroduodenoscopy or colonoscopy, or at least 1 session of double-balloon endoscope therapy or primary medical approaches) or unsuitable for conventional therapies (i.e., multiple lesions, lesions inaccessible by endoscopic therapy or surgery, or patients unwilling or unable to undergo surgery due to poor health condition).

Angiodysplasia at endoscopy was characterized by focal or diffused venous/capillary lesions presenting as bright red ectatic vessels or pulsatile red protrusions, with surrounding venous dilation or patchy erythema with or without oozing, and endoscopic appearance of GAVE was indicated by longitudinal antral folds converging on the pylorus, containing visible columns of tortuous red ectatic vessels.\[22,23\]

Exclusion criteria were: cirrhotic or portal hypertension gastropyth; severe cardiac, pulmonary, renal, liver, pancreas, hematological, or rheumatologic comorbidities, uncontrolled diabetes mellitus or hypertension, or renal insufficiency without hemodialysis or peritoneal dialysis; severe bilateral peripheral neuropathy or seizure, thromboembolic disease, or known thalidomide allergy; treatment with any systemic or oral topical corticosteroids, nonsteroidal antiinflammatory drugs, any putative immunomodulators, or antiangiogenic agents; pregnant or lactating; alcohol and/or drug abuse; or poor compliance.

This study was approved by the ethical committee of the Renji Hospital. The need for individual consent was waived by the committee because of the retrospective nature of the study.

2.2. Thalidomide treatment and management of adverse effects

In our center, patients received thalidomide only when they had 4 or more bleeding episodes a year as defined by a positive immunoassay fecal occult blood test (iFOBT). Patients received 25 mg thalidomide (Changzhou Pharmaceutical Co., Ltd., Changzhou, China) orally 4 times/day for 4 months. During the treatment period, patients were hospitalized and closely monitored for the 1st week or longer, if required. In patients with recurrent bleeding, another course of thalidomide could be prescribed, but the time between courses had to be at least 1 year.

In the case of an adverse effect, the study medication was temporarily interrupted or permanently discontinued based on the seriousness of the effect or tolerability of the patient. During treatment and follow-up, concomitant therapies such as blood transfusions, iron supplementation, use of hemostatic drugs, and any other symptomatic treatments were performed as necessary. If massive bleeding occurred in the context of poor clinical effect of symptomatic treatment, endoscopic treatment, DSA embolism, or surgery were considered.

Packed red cell transfusion was indicated and recorded when the hemoglobin levels fell below 7.0 g/dL (2 U were administered for 6.1 g/dL ≤ hemoglobin < 7.0 g/dL, 3 U for 5.1 g/dL ≤ hemoglobin < 6.0 g/dL, and 4 U for hemoglobin < 5.0 g/dL).\[24\] Iron supplementation was allowed when the hemoglobin levels fell between 7.1 and 11.0 g/dL. All patients were followed up until the last patient had been followed up for 1 year after thalidomide treatment.

2.3. Data collection

Two qualified research nurses collected demographics, medical and family histories, and all clinical data including any adverse effects during follow-up. All physical examinations, treatments, and follow-up were performed by the same 2 qualified doctors. During follow-up, as a standard follow-up procedure, patients had to report the characteristics of their feces (i.e., color, volume, frequency of defecation, and softness) daily in a diary. All patients were requested to visit the hospital monthly during follow-up and biweekly during treatment.

At each scheduled visit, a physical examination, complete blood counts, and routine iFOBT (using monoclonal colloidal gold color technology) were performed. In case of positive iFOBT, with or without any signs of overt bleeding, iFOBT was performed daily until there were 3 consecutive days with a negative test, in order to ensure whether or not bleeding truly occurred, whether or not bleeding was stopped, and how long it lasted. In addition, during the whole study period, iFOBT was performed daily in the same way in patients with any signs of overt bleeding. Serum chemical laboratory tests, blood coagulation tests, and hepatic and renal tests were performed before and after the treatment. Neuropathy and other adverse effects were assessed monthly. A urine pregnancy test for the β-subunit of human chorionic gonadotropin was performed for female patients with childbearing potential before treatment, biweekly during treatment, and 1 month after treatment.

2.4. Treatment response and adverse effects

The patients were divided into 4 groups according to their clinical response after thalidomide treatment: bleeding cessation, bleeding diminution, bleeding diminution when taking thalidomide, and ineffective. Cessation of bleeding was defined as GI bleeding being completely stopped during follow-up. Patients whose yearly bleeding episodes decreased by ≥50% during follow-up were allocated to the bleeding diminution group. Patients whose bleeding stopped when taking thalidomide but relapsed again during follow-up were allocated to bleeding diminution when taking thalidomide group. Patients whose yearly bleeding episodes decreased by <50% during follow-up were attributed to ineffective group.
Short-term recurrence was defined as GI bleeding occurring immediately after drug discontinuation. Long-term recurrence was defined as GIVM recurrence > 1 year after thalidomide discontinuance.

The overall response rate was defined as the proportion of patients in the bleeding cessation, bleeding diminution, and bleeding diminution when taking thalidomide groups.

A bleeding outcome was defined as a positive iFOBT. A bleeding episode was defined as being stopped when there were 3 consecutive days with a negative iFOBT test. All bleeding episodes described in this study were attributed to GIVM.

Adverse effects included any unfavorable changes in health including occurrence or worsening of any clinical symptoms, signs, or abnormal laboratory findings during follow-up. The adverse effects were classified as mild (constipation, somnolence, edema, dizziness, headache, pruritus, and dry mouth) or serious (limb numbness, leukopenia, and rashes).

### 2.5. Statistical analysis

Continuous variables are reported as means ± standard deviation or as median (range), and were analyzed using 2-sample paired t test or Wilcoxon signed-rank test, as appropriate. Categorical variables are presented as frequencies and were analyzed using the Chi-square test or the Fisher exact test, as appropriate. Statistical analysis was performed by a biostatistician blinded to the treatment assignment using SPSS 16.0 (IBM, Armonk, NY). Two-sided P-values < 0.05 were considered statistically significant.

### 3. Results

#### 3.1. Characteristics of the patients

A total of 87 patients diagnosed with GIVM were eligible. Two patients who had severe concomitant diseases were excluded. Three patients refused additional treatments because of drowsiness, constipation, and slight leukopenia. Two patients did not complete the 1-year follow-up. Thus, 80 patients were included. The enrolled subjects in our present study also included thalidomide group patients in our previous study.

Median age was 63.5 (range, 40–87.0) years and most (92.5%, 74/80) were > 50 years old. There were 57 (71.3%) women and 23 (28.7%) men. Seventy (87.5%) patients were complaining of overt bleeding including hematemesis (n = 1), hematochezia (n = 15), and melena (n = 54); 10 patients presented occult bleeding only. The median course of GI bleeding was 22 (range, 1–360) months. During the year prior to treatment, the median number of bleeding episodes was 6 (range, 4–48), the median volume of blood transfusion was 750 (range, 0–15,600) mL, and the median hemoglobin level was 64 (range, 17–113) g/L. Median follow-up was 42.6 (range, 12–120) months.

| Table 1 | Response to thalidomide. |
|---|---|
| First-year of follow-up (n = 80) | Whole follow-up (n = 78) |
| Bleeding cessation | 33 (41.3%) | 30 (38.5%) |
| Decreased bleeding | 22 (27.5%) | 25 (32.1%) |
| Decreased bleeding while being on thalidomide | 7 (8.8%) | 7 (9.0%) |
| Ineffective | 18 (22.5%) | 16 (20.5%) |
| Overall response rate | 62 (77.5%) | 62 (79.5%) |

#### 3.2. Response to treatment

During the 1-year of follow-up, the overall response rate was 77.5% (62 of 80), and the rate of bleeding cessation was 41.3% (33/80). Among the patients with bleeding cessation, 3 had a recurrence after the 1st-year (range, 12–14 months) with 4 to 12 bleeding episodes each year. These 3 patients received a 2nd course of thalidomide. After retreatment, their bleeding episodes decreased significantly.

Among patients with decreased bleeding (bleeding episodes decreased by ≥50% during the 1st-year), 3 patients with increased number of bleeding episodes 12 to 26 months after discontinuation also received a 2nd course of thalidomide and achieved satisfactory effect.

Among patients with decreased bleeding during treatment, 5 patients received a median of 2 courses (range: 2–4) of thalidomide. In the ineffective group, 2 patients had to undergo intestinal resection 12 and 15 months after drug discontinuation. One patient had no recurrence over his 7-year follow-up, while the other had 3 bleeding episodes 3 years after surgery.

The overall response rate of the 78 patients during follow-up was 79.5% (62/78) (Table 1). The recurrence rate of GIVM bleeding after the 1st course of thalidomide was 20.7% (13/62). Among 13 patients with recurrent GI bleeding, 11 patients received thalidomide retreatment with an effective rate of 100%.

After thalidomide treatment, yearly bleeding episodes decreased from 8.0 ± 6.4 (4–48) to 2.3 ± 2.5 (P < 0.001). Yearly blood transfusions decreased from 1386 ± 2166 to 315 ± 645 mL (P < 0.001). The mean hemoglobin levels were increased from 64 ± 2046 to 102 ± 2470 g/L (P < 0.001). The yearly number of hospitalization for bleeding decreased from 3.0 ± 1.8 to 0.8 ± 1.3 (P < 0.001) (Table 2).

| Table 2 | Change of clinical indexes in 80 patients during the entire follow-up. |
|---|---|
| | Before treatment | After treatment |
| Yearly bleeding episodes* | 8.0 ± 6.4* (4–48) | 2.3 ± 2.5* (0–12)* |
| Number of hospitalization* | 3.0 ± 1.8* (1–12) | 0.8 ± 1.30 (0–5)* |
| Blood transfusion, mL* | 1386 ± 2166/750 (0–15,600) | 315 ± 645/0 (0–3700)* |
| Hemoglobin, g/L* | 64 ± 2046 (17–113) | 102 ± 2470 (40–154)* |

Results are shown as mean ± standard deviation/median (range). Yearly data were calculated as the total values of the variables during the whole follow-up divided by the average number of follow-up months, multiplied by 12. *P < 0.001.

Data were compared using Wilcoxon signed-rank test.

### 3.3. Comorbidities

Thirty (37.5%) patients had 1 or several preexisting comorbidities. Three patients had cardiac valve disease. Two of these patients were receiving anticoagulation therapy (warfarin) after cardiac valve replacement, which did not affect the response to thalidomide. The 3rd patient was suffering from aortic incompetence: 2 showed complete bleeding cessation during follow-up and did not show GI bleeding recurrence during the 1st-year, and the rate of bleeding cessation was 41.3% (33/80). Among the patients with bleeding cessation, 3 had a recurrence after the 1st-year (range, 12–14 months) with 4 to 12 bleeding episodes each year. These 3 patients received a 2nd course of thalidomide. After retreatment, their bleeding episodes decreased significantly.

Among patients with decreased bleeding (bleeding episodes decreased by ≥50% during the 1st-year), 3 patients with increased number of bleeding episodes 12 to 26 months after discontinuation also received a 2nd course of thalidomide and achieved satisfactory effect.

Among patients with decreased bleeding during treatment, 5 patients received a median of 2 courses (range: 2–4) of thalidomide. In the ineffective group, 2 patients had to undergo intestinal resection 12 and 15 months after drug discontinuation. One patient had no recurrence over his 7-year follow-up, while the other had 3 bleeding episodes 3 years after surgery.

The overall response rate of the 78 patients during follow-up was 79.5% (62/78) (Table 1). The recurrence rate of GIVM bleeding after the 1st course of thalidomide was 20.7% (13/62). Among 13 patients with recurrent GI bleeding, 11 patients received thalidomide retreatment with an effective rate of 100%.

After thalidomide treatment, yearly bleeding episodes decreased from 8.0 ± 6.4 to 2.3 ± 2.5 (P < 0.001). Yearly blood transfusions decreased from 1386 ± 2166 to 315 ± 645 mL (P < 0.001). The mean hemoglobin levels were increased from 64 ± 2046 to 102 ± 2470 g/L (P < 0.001). The yearly number of hospitalization for bleeding decreased from 3.0 ± 1.8 to 0.8 ± 1.3 (P < 0.001) (Table 2).

#### 3.3. Comorbidities

Thirty (37.5%) patients had 1 or several preexisting comorbidities. Three patients had cardiac valve disease. Two of these patients were receiving anticoagulation therapy (warfarin) after cardiac valve replacement, which did not affect the response to thalidomide. The 3rd patient was suffering from aortic incompetence: 2 showed complete bleeding cessation during follow-up and had a recurrence after 14 months. This patient received a 2nd course of thalidomide, with success. Among these patients, 2 complained of numb limbs.

In 1 patient with hereditary HHT, DSA showed multiple aneurysms, 2 hepatic artery aneurysms, and 1 superior
mesenteric artery aneurysm. Besides, this patient had bilateral nasal mucosa telangiectasia and gastric malformation. After 1 course of thalidomide, her bleeding episodes decreased from 12 to 7 times/year, but with leukopenia.

The overall response rate was 76.7% (23/30) among patients with comorbidities, while the response rate was 78.0% (39/50) among those without comorbidities, without difference between the 2 groups ($P=0.55$) (Table 3).

### 3.4. Adverse effects

Adverse effects were observed in 60.0% (48/80) of the patients. Serious adverse effects were reported in 31.3% (25/80) of the patients. No adverse effect threatened the life of the patients and disappeared or were relieved after discontinuation of thalidomide or symptomatic treatment.

Of the 30 patients with comorbidities, 22 (73.3%) experienced adverse effects including 10 (33.3%) with serious adverse effects. Of the 50 patients without comorbidities, the rate of overall adverse effects and serious adverse effects were 52.0% ($P=0.098$) and 30.0% ($P=0.76$), respectively. There were no differences between the 2 groups (Table 4).

Among the 11 patients with multiple courses of thalidomide treatment, the overall rate of adverse effects and serious adverse effects were 100% (11/11) and 63.6% (7/11), respectively. For patients with a single course of thalidomide, these rates were 53.6% (37/69) ($P=0.002$) and 26.1% (18/69) ($P=0.03$), respectively (Table 5).

### 4. Discussion

Thalidomide may be used for the treatment of GIVM, but the long-term response and adverse effects are unknown. This study aimed to examine the recurrence rate of GIVM bleeding after thalidomide treatment, the response to treatment, and the adverse effects. Results showed that the overall response rate during follow-up was 79.5%. The recurrence rate was 20.7% after the 1st course of thalidomide. The response rate of retreatment was 100%. The overall response rate and adverse effect rate were similar between patients with or without comorbidities.

The efficacy of thalidomide in treating recurrent GI bleeding due to GIVM was previously reported in a number case reports and small case series.[25–27] In this study, the overall effective rates during the 1st year and during the entire follow-up were 77.5% and 79.5%, respectively, similar to our previous randomized controlled study in which the effective rate of thalidomide treatment for GIVM patients was 71.4% during the 1st-year follow-up.[4]

The efficacy and safety of thalidomide for GIVM with comorbidities was only discussed in some case series. Draper et al.[28] prescribed thalidomide to 7 GIVM bleeding patients with left ventricular assisting device implantation. GI bleeding was stopped in 5 patients and significantly reduced in 2 patients. In this study, the overall effective rate and the rate of main adverse effects of thalidomide in the comorbidities group were 76.7% and 33.3%, respectively, which were similar to the rates of 78.0% and 30.0% in patients without comorbidities, but the strict selection criteria in this study may have introduced a selection bias.

Alam et al.[29] reported that thalidomide had a good clinical effect on recurrent GI bleeding from gastric and duodenal angiodysplasias because of hereditary HHT. In this study, 1 patient with gastric body malformation due to HHT failed to respond to thalidomide after 4 months, although her yearly bleeding episodes decreased. This difference might be due to the longer treatment course (16 months) in the study by Alam et al.[29]

Previous studies used thalidomide doses of 50 to 400 mg/day. Considering the older age of the patients (average age, 64.6 years) in this study, a low dose was selected (100 mg daily). In this study, the recurrence rate of GIVM bleeding after the 1st course of thalidomide treatment was 20.7% (13/62). Among these 13 patients with recurrence, 11 patients received an average 2 (range: 2–4) course of thalidomide. All patients had decreased bleeding episodes when taking thalidomide or after another course of medication. The effective rate of thalidomide retreatment was 100%. Meanwhile, the rate of serious adverse effects was 63.6% (7/11), which was higher than the percentage of serious adverse effects after a single course of thalidomide (26.1%, 18/69).

Thalidomide carries the risk of adverse effects such as fatigue, constipation, dizziness, peripheral neuropathy, and edema.[10] In this study, the overall rate of adverse effects was 60.0%. All adverse effects were mild-to-moderate and were relieved or disappeared after discontinuation of thalidomide treatment or symptomatic treatment. A new thalidomide analogue (lenalidomide), which is reported to be a more potent immunomodulator with possibly fewer side effects,[31,32] could be used for the prevention of GI bleeding due to GIVM, but studies are required in this specific population of patients.

In addition to angiogenesis, VEGF is also associated with neural regeneration. Therefore, neurotoxicity is an important adverse effect for antiangiogenic drugs.[19] A study demonstrated that suppressing VEGF level by 25% could lead to motor neuron degeneration.[18] Our previous studies found that thalidomide could inhibit VEGF expression in vivo and ex vivo.[4,33] Cavaletti et al.[34] confirmed that sensory neurotoxicity of thalidomide was found to be dependent upon the cumulative dose but occurred
only when the total dose was relatively high (>20 g); the risk of developing sensory neuropathy was around 10% below this threshold (20 g) but increases with higher doses. In this study, the total dose of a single course of thalidomide was 12 g with a rate of 14.5% of limb numbness, while it increased to 63.6% for 2 or more courses. In a word, results do improve with retreatment but so do the adverse events. A 2nd course of thalidomide treatment should be prescribed with great caution according to risk and benefit of the medication.

Double balloon enteroscopy (DBE) was 1st described in 2001 by Yamamoto et al. It allows deeper intubation of the small bowel (SB) compared with traditional endoscopes and endoscopic treatment of SB disorders. As a general statement, there has been a paucity of data regarding outcomes after endoscopic treatment of SB angioectasia. Samah et al. reported that 97% (129/133) patients with SB vascular lesions were successfully treated with argon plasma coagulation (using DBE). But rebleeding occurred in 45/98 (46%) patients at 36 months. Other recent studies also reported a high rebleeding rate about 35% to 45%. The high rebleeding rate may be related with the multiple and diffuse characteristic of SB vascular lesions. As to thalidomide treatment, there is few study concerned about its rebleeding rate. In our retrospective study, an overall rebleeding rate of 79.5% (62/78) and a relative lower recurrence rate of 21.0% after thalidomide treatment of GIVM were reported. Besides, in 2015, ACG Clinical Guideline also recommend that if a source of bleeding is found by VCE and/or deep enteroscopy in the small intestine that is associated with significant ongoing anemia or active bleeding, then the patient should be managed with endoscopic therapy (strong recommendation, low level of evidence). If bleeding persists or recurs or a lesion cannot be localized consideration may be given to medical treatment with iron, somatostatin analogs, or antiangiogenic therapy (strong recommendation, moderate level of evidence). So, we think endoscopic treatment under DBE may be much better for those isolated or limited vascular lesions, while thalidomide may be suitable for those multiple and diffuse lesions.

The major limitation of this study is that we could not carry out a prospective randomized controlled trial. The natural history of bleeding episodes in GI vascular malformations is unknown and can be very episodic in some patients. In this study, the effective rate of thalidomide treatment and retreatment for GIVM bleeding was defined based on patients’ self-reporting. Concomitant therapies such as blood transfusions, iron supplementation, use of hemostatic drugs, and any other symptomatic treatments were performed as necessary during the whole study. They might mask some of the outcomes like increase in hemoglobin and change in stool color with iron. Self-reporting of stool color might introduce some bias. The strict exclusion criteria by which patients with severe comorbidities were excluded may influence the conclusions. Additional well-designed randomized trials are still required to confirm these findings.

In conclusion, thalidomide might be effective for patients with GIVM bleeding when they relapse or worsen after the 1st course of treatment, but side effects should be closely monitored.

References

[1] Redondo-Cerezo E, Gomez-Ruiz CJ, Sanchez-Manjavacas N, et al. Long-term follow-up of patients with small-bowel angiodysplasia on capsule endoscopy. Determinants of a higher clinical impact and rebleeding rate. Rev Esp Enferm Dig 2008;100:202–7.

[2] Doddia G, Trotman BW. Gastrointestinal angiodysplasia. J Assoc Acad Minor Phys 1997;8:16–9.

[3] Junquera F, Feu F, Papo M, et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology 2001;121:1073–9.

[4] Ge ZZ, Chen HM, Gao YJ, et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology 2011;141:1629–37, e1621–1624.

[5] Barnert J, Meissmann H. Diagnosis and management of lower gastrointestinal bleeding. Nat Rev Gastroenterol Hepatol 2009;6:637–46.

[6] Suh SW, ChoiYS, Kim H, et al. Small bowel ischemia after angiographic embolization for angiodysplasia of lower gastrointestinal tract: the case for conservative management. Clin Res Heparol Gastroenterol 2011;35:819–22.

[7] Di Girolamo G, Malavasi A, Cassilia L, et al. Chronic bleeding caused by small bowel angiodysplasia: a problem of recognition and diagnosis. Ital J Gastroenterol 1992;24:468–9.

[8] Jarbanthan S, van de Veer WM, Mulder CJ. Double-balloon endoscopy in the diagnosis and treatment of hemorrhage from retrovacular angiodysplasias. J Gastrointestin Liver Dis 2008;17:333–4.

[9] Gady JS, Reynolds H, Blum A. Selective arterial embolization for control of lower gastrointestinal bleeding: recommendations for a clinical management pathway. Curr Surg 2003;60:344–7.

[10] Haq AU, Glass J, Netchvolidov CV, et al. Hereditary hemorrhagic telangiectasia and danazol. Ann Intern Med 1998;109:171.

[11] Vujkovic B, Lavre J, Sabovic M. Successful treatment of bleeding from colonic angiodysplasias with tranexamic acid in a hemodialysis patient. Am J Kidney Dis 1998;31:536–8.

[12] Quitt M, Froom P, Vesler A, et al. The effect of desmopressin on massive gastrointestinal bleeding in hereditary telangiectasia unresponsive to treatment with cryoprecipitate. Arch Intern Med 1999;159:1744–6.

[13] Meijer K, Peters FT, van der Meer J. Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand’s disease, controlled with recombinant factor VIIa. Blood Coagul Fibrinol 2001;12:211–3.

[14] Junquera F, Saperas E, Vidal S, et al. Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia. Am J Gastroenterol 2007;102:234–60.

[15] D’Amato RJ, Loughran MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:14082–5.

[16] Junquera F, Saperas E, de Torres I, et al. Increased expression of endostatin and Adjuvant Therapies. Anesthesiology 2006;105:198–208.

[17] Sharma NL, Sharma VC, Mahajan VK, et al. Thalidomide: an experience in therapeutic outcome and adverse reactions. J Dermatol Treat 2007;18:335–40.

[18] Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004;363:1802–11.

[19] Wang XY, Chen Y, Du Q. Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia. Eur Rev Med Pharmacol Sci 2013;17:1114–6.

[20] Garrido Serrano A, Leon R, Sayago M, et al. Thalidomide treatment in cirrhotic patients with severe anemia secondary to vascular malformations. Dig Dis Sci 2012;57:1112–3.

[21] Lee S. Gl-associated hemangiomas and vascular malformations. Clin Colon Rectal Surg 2011;24:193–200.

[22] Ruder JA, Klotz AP, Kruiner JB. Gastritis with veno-capillary ectasia as a source of massive gastric hemorrhage. Gastroenterology 1953;24:118–23.

[23] Jabbari M, Cherry R, Lough JO, et al. Gastric antral vascular ectasia: the watermelon stomach. Gastroenterology 1984;87:1165–70.

[24] American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology 2006;105:198–208.

[25] Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol 2003;98:221–2.

[26] Baudiz J, Schachsgal G, Wedel S, et al. Thalidomide for treatment of severe intestinal bleeding. Gut 2004;55:609–12.

[27] Kamalaporn P, Saravanan R, Cirocco M, et al. Thalidomide for the treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol. J Heart Lung Transplant 2015;34:132–4.

[28] Draper K, Kale P, Martin B, et al. Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol. J Heart Lung Transplant 2015;34:132–4.

[29] Alam MA, Sami S, Babu S. Successful treatment of bleeding gastrointestinal angiodysplasia in hereditary haemorrhagic telangiectasia with thalidomide. BMJ Case Rep 2011;2011.
[30] Corso A, Zappasodi P, Barbarano L, et al. Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide: balancing efficacy and side-effects. Leuk Res 2009;33:e145–9.
[31] Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–32.
[32] Bowcock SJ, Patrick HE. Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias? Br J Haematol 2009;146:220–2.
[33] Lambrechts D, Carmeliet P. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim Biophys Acta 2006;1762:1109–21.
[34] Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131–8.
[35] Tan H, Chen H, Xu C, et al. Role of vascular endothelial growth factor in angiodysplasia: an interventional study with thalidomide. J Gastroenterol Hepatol 2012;27:1094–101.
[36] Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004;62:2291–3.
[37] Yamamoto H, Sekine Y, Sato Y, et al. Total enteroscopy with a nonsurgical steerable double-balloon method. Gastrointest Endosc 2001;53:216–20.
[38] Samaha E1, Rahmi G, Landi B, et al. Long-term outcome of patients treated with double balloon enteroscopy for small bowel vascular lesions. Am J Gastroenterol 2012;107:240–6.
[39] Rahmi G1, Samaha E1, Vahedi K2, et al. Long-term follow-up of patients undergoing capsule and double-balloon enteroscopy for identification and treatment of small-bowel vascular lesions: a prospective, multicenter study. Endoscopy 2014;46:591–7.
[40] Jackson CS, Gerson LB. Management of gastrointestinal angiodysplastic lesions (GIADs): a systematic review and meta-analysis. Am J Gastroenterol 2014;109:474–83.
[41] Gerson LB, Fidler JL, Cave DR, et al. ACG Clinical Guideline: Diagnosis and Management of Small Bowel Bleeding. Am J Gastroenterol 2015;110:1265–87.